EU/3/14/1344: Orphan designation for the treatment of cystic fibrosis
Nitric oxide
Table of contents
Overview
On 15 October 2014, orphan designation (EU/3/14/1344) was granted by the European Commission to PD Dr med. Joachim Riethmüller, Germany, for nitric oxide for the treatment of cystic fibrosis.
Key facts
Active substance |
Nitric oxide
|
Intended use |
Treatment of cystic fibrosis
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/14/1344
|
Date of designation |
15/10/2014
|
Sponsor |
PD Dr med. Joachim Riethmüller
Beethovenweg 7 72076 Tübingen Germany Tel. +49 7071 298 1442 Fax +49 7071 294 450 E-mail: joachim.riethmueller@med.uni-tuebingen.de |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: